A rare large duplication of MLH1 identified in Lynch syndrome.
Genetic predisposition
Lynch syndrome
Mismatch repair genes
Whole-genome sequencing
Journal
Hereditary cancer in clinical practice
ISSN: 1731-2302
Titre abrégé: Hered Cancer Clin Pract
Pays: Poland
ID NLM: 101231179
Informations de publication
Date de publication:
19 Jan 2021
19 Jan 2021
Historique:
received:
09
11
2020
accepted:
05
01
2021
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
21
1
2021
Statut:
epublish
Résumé
The most frequently identified strong cancer predisposition mutations for colorectal cancer (CRC) are those in the mismatch repair (MMR) genes in Lynch syndrome. Laboratory diagnostics include testing tumors for immunohistochemical staining (IHC) of the Lynch syndrome-associated DNA MMR proteins and/or for microsatellite instability (MSI) followed by sequencing or other techniques, such as denaturing high performance liquid chromatography (DHPLC), to identify the mutation. In an ongoing project focusing on finding Mendelian cancer syndromes we applied whole-exome/whole-genome sequencing (WES/WGS) to 19 CRC families. Three families were identified with a pathogenic/likely pathogenic germline variant in a MMR gene that had previously tested negative in DHPLC gene variant screening. All families had a history of CRC in several family members across multiple generations. Tumor analysis showed loss of the MMR protein IHC staining corresponding to the mutated genes, as well as MSI. In family A, a structural variant, a duplication of exons 4 to 13, was identified in MLH1. The duplication was predicted to lead to a frameshift at amino acid 520 and a premature stop codon at amino acid 539. In family B, a 1 base pair deletion was found in MLH1, resulting in a frameshift and a stop codon at amino acid 491. In family C, we identified a splice site variant in MSH2, which was predicted to lead loss of a splice donor site. We identified altogether three pathogenic/likely pathogenic variants in the MMR genes in three of the 19 sequenced families. The MLH1 variants, a duplication of exons 4 to 13 and a frameshift variant, were novel, based on the InSiGHT and ClinVar databases; the MSH2 splice site variant was reported by a single submitter in ClinVar. As a variant class, duplications have rarely been reported in the MMR gene literature, particularly those covering several exons.
Sections du résumé
BACKGROUND
BACKGROUND
The most frequently identified strong cancer predisposition mutations for colorectal cancer (CRC) are those in the mismatch repair (MMR) genes in Lynch syndrome. Laboratory diagnostics include testing tumors for immunohistochemical staining (IHC) of the Lynch syndrome-associated DNA MMR proteins and/or for microsatellite instability (MSI) followed by sequencing or other techniques, such as denaturing high performance liquid chromatography (DHPLC), to identify the mutation.
METHODS
METHODS
In an ongoing project focusing on finding Mendelian cancer syndromes we applied whole-exome/whole-genome sequencing (WES/WGS) to 19 CRC families.
RESULTS
RESULTS
Three families were identified with a pathogenic/likely pathogenic germline variant in a MMR gene that had previously tested negative in DHPLC gene variant screening. All families had a history of CRC in several family members across multiple generations. Tumor analysis showed loss of the MMR protein IHC staining corresponding to the mutated genes, as well as MSI. In family A, a structural variant, a duplication of exons 4 to 13, was identified in MLH1. The duplication was predicted to lead to a frameshift at amino acid 520 and a premature stop codon at amino acid 539. In family B, a 1 base pair deletion was found in MLH1, resulting in a frameshift and a stop codon at amino acid 491. In family C, we identified a splice site variant in MSH2, which was predicted to lead loss of a splice donor site.
CONCLUSIONS
CONCLUSIONS
We identified altogether three pathogenic/likely pathogenic variants in the MMR genes in three of the 19 sequenced families. The MLH1 variants, a duplication of exons 4 to 13 and a frameshift variant, were novel, based on the InSiGHT and ClinVar databases; the MSH2 splice site variant was reported by a single submitter in ClinVar. As a variant class, duplications have rarely been reported in the MMR gene literature, particularly those covering several exons.
Identifiants
pubmed: 33468175
doi: 10.1186/s13053-021-00167-0
pii: 10.1186/s13053-021-00167-0
pmc: PMC7814444
doi:
Types de publication
Journal Article
Langues
eng
Pagination
10Subventions
Organisme : Horizon 2020 Framework Programme ()
ID : No 856620
Organisme : Chinesisch-Deutsche Zentrum für Wissenschaftsförderung
ID : No. M-0008
Organisme : Department of Biotechnology (DBT), Government of India (GOI)
ID : BT/RLF/Re-entry/38/2017
Organisme : European Cooperation in Science and Technology
ID : CA17118
Références
JAMA. 2016 Jan 5;315(1):68-76
pubmed: 26746459
Hum Mutat. 2011 May;32(5):557-63
pubmed: 21520333
N Engl J Med. 2000 Jul 13;343(2):78-85
pubmed: 10891514
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Eur J Cancer. 2020 Jan;125:12-21
pubmed: 31830689
J Mol Diagn. 2010 Jan;12(1):82-90
pubmed: 20007843
Hum Mutat. 2016 Mar;37(3):235-41
pubmed: 26555599
Eur J Hum Genet. 2007 Mar;15(3):383-6
pubmed: 17228328
JAMA Oncol. 2020 Oct 30;:
pubmed: 33126242
Annu Rev Biochem. 2005;74:681-710
pubmed: 15952900
Annu Rev Genomics Hum Genet. 2019 Aug 31;20:293-307
pubmed: 30848956
Int J Cancer. 2017 Apr 1;140(7):1510-1516
pubmed: 28006863
Ann Oncol. 2004;15 Suppl 4:iv283-4
pubmed: 15477322
Int J Clin Oncol. 2019 Sep;24(9):999-1011
pubmed: 31273487
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Nucleic Acids Res. 2000 Jan 1;28(1):352-5
pubmed: 10592272
Biomed Res Int. 2013;2013:219897
pubmed: 23484096
Nat Genet. 2019 Jan;51(1):76-87
pubmed: 30510241
Hum Genet. 2004 Oct;115(5):432-8
pubmed: 15340835
Clin Genet. 2006 Jan;69(1):40-7
pubmed: 16451135
Cancer Genet. 2018 Feb;221:19-24
pubmed: 29405992
Mol Aspects Med. 2019 Oct;69:10-26
pubmed: 30862463
J Biochem Biophys Methods. 2002 Mar 4;51(1):89-100
pubmed: 11879922
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Nat Struct Mol Biol. 2013 Apr;20(4):461-8
pubmed: 23435383
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Fam Cancer. 2013 Jun;12(2):175-80
pubmed: 23443670
J Clin Oncol. 2015 Feb 10;33(5):426-32
pubmed: 25559809
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
Genome Biol. 2016 Jun 01;17(1):118
pubmed: 27250555
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669